Efficacy and tolerability of pharmacotherapy for obsessive-compulsive personality disorder: a systematic review of randomized controlled trials

Expert Opin Pharmacother. 2022 Aug;23(11):1351-1358. doi: 10.1080/14656566.2022.2100695. Epub 2022 Jul 15.

Abstract

Introduction: Although obsessive-compulsive personality disorder (OCPD) is one of the most prevalent personality disorders, it is one of the least studied. There is debate as to whether pharmacotherapy is efficacious for OCPD. We aimed to systematically evaluate the efficacy and tolerability of pharmacotherapy for OCPD.

Areas covered: This systematic review found two randomized controlled trials investigating pharmacotherapy of OCPD. In a study of major depression (n = 308) with comorbid OCPD (n = 71), citalopram was more effective for OCPD than sertraline with fewer drop-outs from treatment. In a small study of OCPD (n = 24), fluvoxamine was more effective than placebo, and there was a low drop-out rate. Risk of bias and quality assessment of these studies was not possible, and findings have very low levels of certainty.

Expert opinion: Two studies provide preliminary evidence in support of citalopram and fluvoxamine for OCPD. Further randomized controlled trials are required before firm conclusions can be drawn regarding efficacy of pharmacotherapy for OCPD.

Keywords: Anankastic personality disorder; antidepressants; drug treatment; efficacy; obsessive-compulsive personality; pharmacology; pharmacotherapy.

Publication types

  • Systematic Review

MeSH terms

  • Citalopram / adverse effects
  • Compulsive Personality Disorder* / therapy
  • Fluvoxamine / adverse effects
  • Humans
  • Obsessive-Compulsive Disorder* / drug therapy
  • Randomized Controlled Trials as Topic

Substances

  • Citalopram
  • Fluvoxamine